The kallikreins and kallikrein-related peptidases are serine proteases that control a plethora of developmental and homeostatic phenomena, ranging from semen liquefaction to skin desquamation and blood pressure. The diversity of roles played by kallikreins has stimulated considerable interest in these enzymes from the perspective of diagnostics and drug design. Kallikreins already have well-established credentials as targets for therapeutic intervention and there is increasing appreciation of their potential both as biomarkers and as targets for inhibitor design. Here, we explore the current status of naturally occurring kallikrein protease-inhibitor complexes and illustrate how this knowledge can interface with strategies for rational re-engineering of bioscaffolds and design of small-molecule inhibitors.
Introduction
The kallikrein peptidase family
The extended kallikrein peptidases are defined by homology to either of two ancestral serine proteases, plasma kallikrein or tissue kallikrein, which differ in their gene location, sequence and structure. Whereas plasma kallikrein (KLKB1, located at 4q34-q35) has no related homologue, the tissue kallikrein-related peptidases (KLKs) form a highly conserved multi-gene locus encoding enzymes with either trypsin-or chymotrypsin-like activity Clements et al., 2004) . Fifteen KLKs have been characterised to date, arranged as a tandemly clustered array on chromosome 19q13.3-13.4 (Clements et al., 2004) . This represents the largest known continuous collection of proteases within the human genome (Puente et al., 2003) .
Typically, KLK proteins are produced according to strict temporal and spatial expression patterns and function in regulated activation cascades, suggesting an involvement in a diverse range of physiological processes (Pampalakis and Sotiropoulou, 2007) . Both liver-derived KLKB1 and tissuederived KLK1, as well as KLK2 and KLK12 in vitro (Giusti et al., 2005) , participate in the progressive activation of bradykinin, a bioactive peptide involved in blood pressure homeostasis and inflammation initiation (Bhoola et al., 1992) . Although this is the only demonstration of classical kininogenic activity that was the original hallmark of kallikrein proteases, the contribution of subsets of KLKs to vital physiological processes is well appreciated. Prostateexpressed KLK2, 3, 4, 5 and 14 are involved in seminogelin hydrolysis (Lilja, 1985; Deperthes et al., 1996; Takayama et al., 2001b; Michael et al., 2006; Emami and Diamandis, 2008) , KLK6 and 8 have reported functions in defining neural plasticity (Shimizu et al., 1998; Scarisbrick et al., 2002; Tamura et al., 2006; Ishikawa et al., 2008) and KLK5, 7, 8 and 14 assist in epidermal remodelling via controlled proteolysis of corneodesmosomal proteins (Caubet et al., 2004; Brattsand et al., 2005; Stefansson et al., 2006; Kishibe et al., 2007) . These kallikrein-driven phenomena are critical processes within the prostate, central nervous system and skin, respectively.
In parallel to identification of the kallikrein locus (and serine proteases generally), attempts have been made to produce inhibitors to regulate these enzymes and thus maintain the delicate homeostatic balance between degradation and synthesis in crucial biological pathways. It has been unequivocally shown that failure of inhibition in kallikreinrelated pathways causes detrimental effects that in turn have led to a burgeoning interest in the design and synthesis of kallikrein-specific inhibitors.
Kallikrein structure
Collectively, the KLKs exhibit a number of structural and functional similarities that need to be considered and can be exploited in targeted inhibitor design. All tissue KLK genes consist of five exons of almost identical size with intermittent introns displaying a fully conserved phase ). This has consequences in terms of translated protease sequence; each KLK contains the conserved serine protease catalytic triad (His57, Asp102, Ser195) and N-terminal regulatory pre-and pro-sequences, meaning that KLKs are expressed as inactive precursors (zymogens). Although the sequence homology within the classical KLK cluster (KLK1-3) is markedly higher (62-72%) than similarities with any of the more recently characterised KLKs (25-49%) (Harvey et al., 2000) , emerging crystallographic (A) Ribbon plot of KLK1 (PDB accession no. 1SPJ) as a representative KLK structure. b-Sheets and a-helices are shown in yellow and blue, respectively, with important features highlighted in green and purple, with catalytic residues displayed as stick models. (B) Sequence similarity between KLK1-15 and KLKB1 mapped onto the surface of b-trypsin with conservation visualised as a gradient from blue (high), cyan, green and light green to yellow (low). The alignment was produced in Swiss-PdbViewer 4.0.1 using the KLK1, 3-7, KLKB1 and btrypsin crystal structures (PDB accession nos. 1SPJ, 2ANY, 2ZCH, 2BDH, 2PSX, 1L2E and 2QXI, 1SFI) and KLK2 and 8-15 models created using Swiss Model (Guex et al., 2009 ). (C) Structural alignment of sequence conservation between KLK1-15, KLKB1 and btrypsin. Location of b-sheets and a-helices are indicated by yellow arrows and blue cylinders, respectively, with catalytic residues shown in cyan. Important features are highlighted in green and purple and cysteine residues participating in disulfide bonds are shown in yellow.
Completely conserved residues and conservative substitutions are shown in dark grey and light grey, respectively. studies have revealed that KLK tertiary structure across the locus is highly conserved (Figure 1) . Indeed, the kallikrein 'molecular chassis' conforms to the canonical trypsin fold, consisting of an almost entirely b-sheet arrangement (SCOP trypsin-like serine proteases; SCOP ID 50493). Furthermore, although the KLKB1 gene encodes four additional N-terminal domains, its level of sequence similarity across the catalytic domain is not dissimilar to that observed for the tissue KLK locus (Figure 1 ).
Rationale for kallikrein inhibition
Consistent with the important role of kallikrein proteases in normal physiology, defective control of expression or activity is strongly linked to development of disease. Most prominent is the potential significance of KLKs to certain cancers typified by aberrant KLK expression including lung, pancreatic, colon (Yousef et al., 2004) and hormone-dependent cancers, particularly those of the prostate (Magklara et al., 2000; Petraki et al., 2003; Veveris-Lowe et al., 2005) , ovaries (Dong et al., 2001; Yousef et al., 2003; Prezas et al., 2006) and breast (Yousef et al., 2002; Zhang et al., 2006; Pampalakis et al., 2009) . Contrasting effects of KLK overexpression on cancer physiology have been proposed. KLK overexpression can provide a pathway for tumour development and metastasis by degrading the restrictive localised tissue architecture and shifting the cellular signalling axis to drive increased proliferation. Alternatively, differential KLK expression can have a protective function in certain cancers. A considerable amount of research has been devoted to exploring the utility of KLK panels as hormone-dependent cancer biomarkers Clements et al., 2004) . KLK3 (prostate-specific antigen, PSA) remains the gold-standard biomarker for prostate cancer diagnosis and prognosis (Stamey et al., 1987; Catalona et al., 1991) , albeit with some degree of controversy.
In the context of the skin, a role for KLKs has been identified in the rare but severe disorder Netherton syndrome (OMIM: 256500) (Chavanas et al., 2000; Descargues et al., 2005; Briot et al., 2009) , as well as the milder but much more frequent condition acne rosacea (Yamasaki et al., 2007; Stefansson et al., 2008) . Furthermore, KLK1 and KLKB1 have been implicated in a number of diseases associated with dysregulation of the kallikrein/kinin system, such as cardiovascular, renal, inflammatory and gastrointestinal tract disease (Devani et al., 2002; Stadnicki et al., 2003) . Finally, KLK6 and KLK8 have potential roles in neurodegenerative conditions such as Alzheimer's disease (Little et al., 1997; Shimizu-Okabe et al., 2001) , multiple sclerosis (Terayama et al., 2005; Scarisbrick et al., 2008) , epilepsy , synucleinopathies (Iwata et al., 2003) and general central nervous system inflammation (Blaber et al., 2004) . The identification of dysfunctional KLK activity as a major pathological influence suggests that targeted inhibition of relevant KLKs is likely to be an effective therapeutic strategy.
Transient inhibition of certain kallikrein-mediated processes has already been explored and the use of aprotinin to reduce peri-operative bleeding in cardiac surgery by inhibiting proteases involved in haemostatic and inflammatory processes was widespread (Fritz and Wunderer, 1983; Terrell et al., 1996) . Although initially thought to be successful, this therapy has recently been withdrawn from use following the result of several larger clinical trials that were terminated before completion because of a persistent trend of increased mortality (Murkin, 2009) . Since this outcome is very recent, the probable physiological explanation is yet to be determined, although one might speculate that it involves interference with unrelated biological pathways owing to the broad range activity of aprotinin, much like the first-generation matrix metalloprotease (MMP) inhibitors.
Naturally occurring kallikrein inhibitors
Although proteases drive numerous vital physiological processes, activity must be tightly regulated to ensure correct spatial and temporal delivery. The function of mature proteases is commonly controlled by protein-based inhibitors that adopt the form of a non-hydrolysable substrate. Whereas almost all inhibitors bind to their cognate protease via an exposed motif, the mechanism by which they achieve inhibition varies from canonical inhibitors that simply block the protease active site to serpins that irreversibly disturb the delicate conformation of the protease (Laskowski and Kato, 1980) . A number of canonical and serpin inhibitors of KLK proteases have been identified. These include physiological inhibitors that provide an essential regulatory influence on KLK-mediated processes and activation cascades, as well as broad-range, exogenous inhibitors that function as valuable research tools for determining the significance of KLK activity in experimental systems. Notable KLK inhibitors are discussed in more detail below and a comprehensive inhibitory profile of natural and engineered inhibitors is provided in Figure 2A -D.
Canonical inhibitors
Standard-mechanism or canonical inhibitors currently form the largest class of protein-based inhibitors. Here, protease inhibition generally involves contact with the target protease via the canonical loop, a characteristic exposed binding motif on the inhibitor surface that is complementary to the activesite cleft. This interaction is often referred to as analogous to the formation of a protease-substrate complex, since both are non-covalent, tight-binding and reversible with contact occurring across extended b-sheets (Tyndall et al., 2005) . However, in the protease-inhibitor complex, hydrolysis of the reactive-site P1-P19 peptide bond is rare, preventing subsequent dissociation of the complex and temporarily removing the ability of the protease to bind substrate (Laskowski and Kato, 1980) . The importance of this binding mechanism is highlighted by the fact that the conformation of the canonical loop is very similar, even among diverse families of protease inhibitors ( Figure 2E ).
Kunitz-domain inhibitors
Canonical inhibitors of this class are characterised by the Kunitz domain, a motif spanning 50-60 residues that contains the inhibitory binding loop within a central anti-parallel b-sheet ( Figure 2E ). Considerable rigidity across the domain is imparted by a network of conserved disulfide bonds (Hynes et al., 1990; Perona et al., 1993) . Most prominent is bovine pancreatic trypsin inhibitor (BPTI), also previously referred to as kallikrein inactivator, aprotinin or trasylol. Following isolation and crystallisation from bovine pancreatic tissue extracts, biochemical characterisation revealed that BPTI was a potent inhibitor of not only bovine trypsin, but also KLKB1 (Kraut et al., 1930) . Later studies that extended to the classical tissue kallikrein locus reported inhibitory activity against KLK1 (Hofmann and Geiger, 1983) and KLK2 (Geiger et al., 1980) . More recently, BPTI/aprotinin has been widely used as a non-specific reagent to block the activity of kallikrein proteases in vitro, including KLK7 (Lundstrom and Egelrud, 1988) , KLK5 and 14 , and KLK2 and 4 (Mize et al., 2008) .
BPTI has no homologue expressed in humans and therefore is not an endogenous modulator of kallikrein proteases, but several potent inhibitors of KLKB1 and KLK1 have been isolated from human tissue, including tissue factor pathway inhibitor-2 (TFPI-2) (Petersen et al., 1996) and Kunitz-type protease inhibitor domains from Alzheimer amyloid precursor protein (APP) and its homologue APPH (Petersen et al., 1994) . A further KLKB1 and KLK1 inhibitor, serine peptidase inhibitor Kunitz-type 2 (SPINT2) was later isolated from human placental tissue and termed bikunin because of its double-headed Kunitz domain structure (Delaria et al., 1997) . Plant material has also proven to be a rich source of Kunitz-type compounds that inhibit KLKs; KLKB1 (Oliva et al., 1999) , KLK7 (Lundstrom and Egelrud, 1988) , KLK5 and 14 are inhibited by soybean trypsin inhibitor (SBTI). Inhibition of KLKB1 has also been demonstrated using novel compounds from Enterolobium, Leucaena, Swartzia and several Bauhinia species (Sampaio et al., 1996) , as well as Caesalpinia echinata kallikrein inhibitor (CeKI) (Cruz-Silva et al., 2004) .
Kazal-domain inhibitors
Lympho-epithelial Kazal-type-related inhibitor (LEKTI) is produced as a multi-domain serine protease inhibitor encoded by the SPINK5 gene (chromosome 5q31-32) (Magert et al., 1999) . Within the skin and thymus, the LEKTI pro-protein is processed into up to 15 individual subunits. Structurally, the resulting fragments are typified by a Kazal-like domain arrangement; an anti-parallel b-sheet bordered by two short a-helices is held together by conserved disulfide links. Most LEKTI domains carry basic residues (Arg or Lys) at their putative P1 sites, suggesting that trypsin-like proteases are likely targets for LEKTI-derived peptides (Magert et al., 1999) . A range of LEKTI fragments can modulate KLK activity, albeit with differing efficiency; KLK5, 7 and 14 are inhibited by LEKTI D8-11 and LEKTI D5 (Deraison et al., 2007) , and KLK5 and 7 are inhibited by LEKTI D6-99 (Schechter et al., 2005) and LEKTI D6 . This activity, in synergy with physiological factors such as pH, provides an essential regulatory influence on the cascade of kallikrein proteases associated with desquamation (Borgono et al., 2007b; Deraison et al., 2007 ). An additional SPINK-related product, LEKTI2 encoded by SPINK9, has recently been identified within the skin and shows KLK5-specific inhibition restricted to the palmoplantar epidermis (Brattsand et al., 2009; Meyer-Hoffert et al., 2009 ).
Other canonical inhibitors
Aside from the classical Kunitz-and Kazal-type inhibitors, several other prominent canonical inhibitors of KLKs have been identified. Purified from the periplasm of Escherichia coli, ecotin is a 32-kDa dimeric serine protease inhibitor with broad-range activity. Characterisation revealed that it is a very potent inhibitor of proteases of the contact activation system, including KLKB1 (Ulmer et al., 1995) . Hirustasin, a serine protease inhibitor isolated from the medical leech Hirudo medicinalis, contains a single antistasin-like domain and is a potent inhibitor of KLK1, but not KLKB1 (Sollner et al., 1994) . A detailed investigation of KLK inhibitors isolated and purified from stratum corneum extracts identified the elafin-like protease inhibitor antileukoprotease as a skinexpressed KLK7 inhibitor and the potato type-1 inhibitor eglin C as an exogenous inhibitor (Franzke et al., 1996) . More recently, several KLK inhibitors have been isolated from plant material; Cucurbita maxima trypsin inhibitor (CMTI) -I and -II exhibit inhibitory activity against serine proteases of the clotting cascade, including KLKB1 (Grzesiak et al., 2000a) , and sunflower trypsin inhibitor (SFTI) is a non-specific Bowman-Birk-like inhibitor of KLK4 (Swedberg et al., 2009 ).
Serpins
Abundant in circulating human plasma, serpins are large protein-based inhibitors that irreversibly attenuate the activity of their target protease. Like canonical inhibitors, contact with the protease is made via an extended b-sheet ( Figure  2E ). However, the serpin mechanism of inhibition is unique in that it is characterised by catalysis of the P1-P19 peptide bond, which causes both a change in the serpin conformation and formation of a protease-inhibitor covalent bond (Loebermann et al., 1984) . Recent crystallographic studies have further clarified this phenomenon. Since the protease is tightly linked to the inhibitor, the serpin structural change due to cleavage at the reactive centre induces a shift in conformation of the bound protease (Huntington et al., 2000) . The resulting loss of protease structure has terminal effects on catalytic ability, namely distortion of the catalytic triad via displacement of Ser195 and collapse of vital interactions formed during zymogen activation (Huntington et al., 2000) .
Several endogenous serpin KLK inhibitors have been identified to date. Best characterised are those found in the circulating plasma, such as a 2 -macroglobulin, antithrombin III, a 1 -antitrypsin, a 2 -antiplasmin and protein C inhibitor, which inhibit KLKB1 (Gallimore et al., 1979; Schapira et al., 1982) , KLK2 (particularly protein C inhibitor) (Deperthes et al., 1995; Frenette et al., 1997) and KLK3 (Christensson et al., 1990) . The search for additional serum-based inhibitors for KLK1 other than a 1 -antitrypsin (Geiger et al., 1981) led to the isolation and characterisation of kallistatin, a novel 58-kDa serpin that complexes with KLK1 in vitro more readily than other circulating inhibitors (Zhou et al., 1992) . Furthermore, the recently identified interaction between KLK8 and serpin B6 (Scott et al., 2007 ) is of particular interest since inhibition of KLK8 by common skin-based inhibitors (such as LEKTI fragments) is yet to be successfully achieved. Serpin inhibition of KLK5, 7, 8 and 11-14 has also been examined in vitro using a 1 -antitrypsin, a 1 -antichymotrypsin, kallistatin, antithrombin-III, protein C inhibitor, plasminogen activator inhibitor-1, a 2 -antiplasmin and C1 inhibitor (Luo and Jiang, 2006) .
Divalent ions
Although not strictly defined as protease inhibitors, several divalent ion species also show an ability to modulate KLK protease activity. Initially, studies were confined to the classical KLK cluster and it was demonstrated that prostateexpressed KLK2 and KLK3 are inhibited by zinc (Lovgren et al., 1999; Malm et al., 2000) . KLK3 is also inhibited by copper, mercury, cobalt and cadmium ions in vitro, although the extent of inhibition is considerably weaker (Malm et al., 2000) . More recently, zinc inhibition of KLK4 (Debela et al., 2006a) , KLK5 (Michael et al., 2006; Debela et al., 2007a) , KLK7 (Debela et al., 2007b) , KLK8 (Kishi et al., 2006) and KLK14 (Borgono et al., 2007c ) was demonstrated and corresponding crystallographic approaches suggest a potential molecular mechanism for inhibition, at least for certain KLKs. For both KLK5 and KLK7, metal ion binding is coordinated by exposed His residues (His96 or His99 for KLK5 and His99 for KLK7) (Debela et al., 2007a,b) . The bound divalent ion subsequently interacts with the catalytic His57 residue, displacing it from the active site. KLK4 is subtly different in that the metal ion binding site is produced by His25 and Gln77 (Debela et al., 2006a) .
Naturally occurring inhibitors have evolved over time to function in a temporal and spatial manner that elegantly offsets their broad-range activity. However, since disease pathogenesis is highly complex and can involve partial or even multiple protease cascades, and since treatments are often administered systemically, therapeutic inhibition must be highly specific with low levels of off-target inhibition. This explains why natural inhibitors, although effective at regulating key physiological processes, very rarely have appreciable value as therapeutics. Therefore, the focus has shifted to engineered inhibitors that can deliver the require selectivity.
Inhibitor engineering Design challenges: potency and specificity
Protease inhibitors require high affinity if they are to be successful as therapeutic agents. The evolution of HIV-1 protease inhibitors revealed important design strategies when analysed from a thermodynamic viewpoint (Freire, 2006) . The affinity of the inhibitor for the protease is determined by the Gibbs free energy of binding, with enthalpy and entropy changes corresponding to different types of atomic interactions (Freire, 2006) . The change in enthalpy is proportional to the strength of binding between the inhibitor and the protease, such as hydrogen bonds, van der Waals interactions and salt bridges. However, in aqueous medium the entropy increases on binding because water molecules are freed from solvation layers around hydrophobic areas and thus become less ordered. Therefore, to achieve maximum affinity, hydrophobic repulsion from the aqueous medium must be combined with strong inhibitor-protease interactions achieving favourable entropy and enthalpy. The first-generation HIV-1 protease inhibitors (indinavir, nelfinavir and saquinavir) were characterised by favourable entropy but unfavourable enthalpy (Velazquez-Campoy et al., 2001) , whereas second-generation inhibitors exhibited both favourable enthalpy and entropy with resulting higher affinity (Ohtaka and Freire, 2005) . It thus appears that finding a balance between enthalpic and entropic changes on inhibitor-protease binding is vital for high-affinity inhibitors.
The importance of inhibitor selectivity is underlined by the high profile failure in clinical trials of a series of MMP inhibitors. These were designed to block MMP-mediated remodelling of the cellular microenvironment and thus halt tumour growth and metastasis (Zucker et al., 2000) . Unfortunately, the majority have been terminated following Phase III trials because of a lack of or even negative survival benefits. Critical evaluations of MMPI performance concluded that this was due, at least in part, to their broad-spectrum activity (Zucker et al., 2000; Coussens et al., 2002; Overall and Lopez-Otin, 2002; Turk, 2006) . This resulted in blockade of important off-target cellular processes that were in fact anti-tumourigenic (Vazquez et al., 1999) , as well as activation of pro-tumorigenic signalling pathways (Maquoi et al., 2002) or interference with unrelated functions with detrimental side effects, such as tendonitis-like musculoskeletal pain (Giavazzi et al., 1998) . Selective inhibitors can be designed by exploiting unique structural features within the active site. These can be identified by screening high-affinity ligands against a panel of the most closely related proteases to establish selectivity, which, in the case of a KLK, should include all related tryptic or chymotryptic members of the family.
Design challenges: mapping the KLK active site
The twin goals of specificity and potency described above are attainable provided the engineered inhibitor has a completely complementary fit with the active site of its target protease. Accordingly, irrespective of the inhibitor being Figure 3 Phage-display cycle. Genetic diversity is generated by ligating degenerate oligonucleotides into the genome of filamentous bacteriophage (typically M13) to produce fusion proteins with pIII, pV or pVII bacteriophage coat proteins. The resultant bacteriophage library is then allowed to interact with an immobilised bait molecule (BINDING) after which weakly bound bacteriophages are removed by washes of increasing stringency (WASH) prior to harvesting of more specifically bound bacteriophage particles by cycles of high-and low-pH washing (ELUTE). The resulting eluate is then reamplified in an E. coli bacteriophage propagation strain (AMPLIFY) and iteratively screened and amplified through a further three or four cycles to produce a final library through pseudo-evolutionary selection. Individual clones from this library are then sequenced and validated through interaction or inhibition assays. designed, the first step is to probe the active site of the target enzyme. The most common strategies revolve around mapping the active site of the target protease through bacteriophage display, positional scanning and sparse matrix substrate libraries.
Bacteriophage display (or biopanning) exploits the physical link between peptides on the exterior of the bacteriophage particle and the genetic material that carries the code for it. In its simplest form, phage display parallels natural evolution, with subpopulations of genetically diverse bacteriophage libraries iteratively selected and amplified by binding to an immobilised target; see Smith and Petrenko (1997) for a review. This technique has been spectacularly successful as a tool for sampling the chemical landscape of short peptides and monoclonal antibodies, resulting in a series of drugs currently available in the clinic, including Avastin, Rituxan and Lucentis (Dimitrov and Marks, 2009 ). An ingenious twist in the application of phage display has refocused this technique as a tool for discovering protease cleavage specificities. This strategy turns the affinity maturation concept on its head so that non-selected sequences are immobilised on a solid support and sequences are selected following cleavage from the solid support. This technique, which was pioneered by Matthews and Wells (1993) revolves around expression of the bacteriophage pIII protein as a fusion protein with an affinity tag, with the pIII portion of the fusion protein being separated from the affinity tag by a randomised sequence. The resulting bacteriophage library is then immobilised on an affinity matrix specific for the fusion partner on the modified pIII protein. Bacteriophages that have linker sequences that are substrates for a given protease will be cleaved off the solid support and can be harvested by filtration and subject to affinity maturation through iterative cycles of amplification, immobilisation and cleavage (Figure 3 ). To date, this technology has been applied to KLKB1 , KLK2 (Cloutier et al., 2002) , KLK3 (Coombs et al., 1998) , KLK6 (Sharma et al., 2008) and KLK14 (Felber et al., 2006) . These studies in turn guided the design of the engineered bioscaffolds discussed below.
The strength of phage display lies in the magnitude and diversity of the libraries that can be screened. However, the screening technique itself is not without inherent bias and blind spots. In particular, pIII fusion peptides have the potential to modulate bacteriophage infectivity. In turn, this can lead to under-or over-representation of particular sequences during screening through their ability to propagate during reamplification rather than by virtue of their affinity for an immobilised ligand (Wilson and Finlay, 1998) . Peptide sequences can also be strongly selected by the solid support used for immobilisation of the target protease. Immobilised metal affinity chromatography (IMAC) is notorious for its ability to select for pIII fusion proteins with multiple histidine residues. These issues are highlighted by studies by Cloutier et al. (2002) that identified peptide substrates for KLK2 using phage display. Although a number of substrates for the enzyme were identified, none of these achieved the catalytic efficiency of the control substrate (TFRSA), nor was this sequence selected. However, this may reflect the fact that assays were based on peptide hydrolysis whereas selection was carried out on the basis of protein cleavage.
Selection bias inherent in biological libraries is circumvented by the positional scanning synthetic combinatorial library (PS-SCL) approach, which uses solid-phase chemistry to generate diversity. It consists of sub-libraries of peptides for each binding subsite of the protease; thus, if the P1-P4 sites are to be investigated, four sub-libraries are needed. These contain 20 pools of peptides, each with a different fixed amino acid for that protease subsite (P1, P2, P3 or P4), whereas the other positions have a mixture of all amino acids (Dooley and Houghten, 1993) . By screening the rate of proteolysis against all 80 pools, the individual contribution of each amino acid at each subsite to substrate recognition or inhibitor binding is revealed. Positional scanning has been used to probe the active site of a number of KLKs; the outcomes are summarised in Table 1. Although this information is invaluable, it is important when interpreting PS-SCL data to be conscious of the assumptions on which the method is based. First, it is assumed that the contributions of each position to biological activity are independent of each other. One argument against this is what can be termed P-site overlap: although the results from the screen indicate that the same residue is favoured in adjacent positions, when assayed as an individual peptide, this is not the case. Two PS-SCL studies of KLK4 ranked Gln favourably for the P2 and P3 positions (Matsumura et al., 2005; Debela et al., 2006b) , whereas assays of individually synthesised peptides revealed that Gln is only favoured R/K n/a n/a n/a Peptides Rajapakse et al., 2005 KLK9 n/a n/a n/a n/a n/a n/a KLK10
M)n)A L)A/M/Q)n Y)V)M/n/I V)M/A/Q)T PS-SCL Debela et al., 2006b KLK4 R)K Q)T/L)V)P V)Q)T)S/A F)I)V)Y/W

R)K/n/M D)E/R)K/M E/D)S/Y/M M)D/E/V/n PS-SCL Debela et al., 2006b KLK11 M)n)K/R)A R)K/D)E)S D/E/M)Y)S M)D/E/V/M PS-SCL Debela et al., 2006b KLK12
K)R n/a n/a n/a Peptides Memari et al. R n/a n/a n/a Peptide Takayama et al., 2001a Amino acids are shown in one-letter code, with 'n' representing norleucine. Bold font indicates the most preferred residue at each subsite. When several sources of data were available, selections were made according to the following priority order: Sparse Matrix Library (SML), Positional Scanning Synthetic Combinatorial Library (PS-SCL), Phage Display Library (PDL) and peptides. n/a, not applicable.
at these subsites if one but not both Gln are present (Swedberg et al., 2009 ). This suggests that the residue interacts with an area of the protease accessible from both subsites. Another misconception is that PS-SCL results can be universally applied to protein substrates. A PS-SCL study of KLK3 revealed a strong preference for Met at the P1 site (Table 1) , although comparison with known cleavage sites for protein substrates indicates that Tyr and Gln are preferred (Merops database, http://merops.sanger.ac.uk/). An inspection of the S1 pocket of the KLK3 structure suggests that it is too narrow to fit Tyr or Gln, but not Met. Therefore, it may well be that binding of a larger protein substrate, which occurs over a considerably larger surface area, causes an induced fit and enables access to larger residues such as Tyr and Gln.
A final inherent problem of the PS-SCL method is the assumption that all amino acid couplings occur with the same efficiency. Considering the popularity of the PS-SCL method, it is surprising that very few examinations of differential reaction rates in mixtures of amino acids have been made. Early solid-phase experiments noted differential reaction rates (Bayer and Hagenmaier, 1968; Ragnarsson et al., 1971 Ragnarsson et al., , 1974 Sandberg and Ragnarsson, 1974) and compensation methods were later used to solve this problem (Kramer et al., 1993; Ostresh et al., 1994; Ivanetich and Santi, 1996) . This issue has been highlighted by Boutin et al. (1997) , who found ten-fold variations in concentration between different sequences and an absence of 35% of all theoretical sequences. These findings may explain why two PS-SCL (Matsumura et al., 2005; Debela et al., 2006b ) screens did not detect the strong preference of KLK4 for Phe at P4 (Swedberg et al., 2009) .
To overcome these problems, positional preferences suggested by PS-SCL can be verified by screening against a sparse matrix library, a small sub-library of individually synthesised and verified peptides (typically 50-200 members) selected from the PS-SCL (Swedberg et al., 2009 ). This strategy is complementary to the positional scanning approach, but circumvents the problems of subsite cooperativity and incomplete and under-represented sequences. In addition, since each peptide is individually assayed, there is often far greater selectivity apparent for each position in the peptide.
Design challenges: bioavailability and stability
For protease inhibitors to be viable therapeutic agents, they must be not only potent and specific towards their target protease, but also readily bioavailable (Fear et al., 2007) . The bioavailability of a drug in a particular tissue is governed by its ability to cross biological barriers to reach the site versus its rate of degradation and excretion. Orally bioavailable drugs in humans commonly fulfil Lipinski's rule of five, which states that the compound should contain not more than five hydrogen bond donors or ten acceptors, an octanol-water partition coefficient of less than five and a molecular mass below 500 Da (Lipinski et al., 2001) . Conversely, the potency of inhibition depends on the number and nature of contact points between the protease and inhibitor, whereas specificity relies on their uniqueness. Therefore, the design of potent, specific and bioavailable KLK inhibitors represents quite a challenge, especially considering the high level of conservation among the KLKs described earlier (Figure 1 ).
Methods that both reduce enzymatic degradation and renal clearance of peptide and protein drugs include polysialylation and PEGylation, in which polysialic acid or poly (ethylene glycol) is attached to one or both termini of the peptide/protein. Polysialylation is a natural strategy to improve peptide and protein half-life (Jain et al., 2004) and was recently used to increase the in vivo availability of an antitumour monoclonal antibody (H17E2 Fab fragment) by a factor of five (Constantinou et al., 2008) . PEGylation is approved by the FDA as a vehicle for pharmaceuticals (Harris and Chess, 2003) and is used in a number of proteinbased drugs currently on the market (Veronese and Harris, 2008) with an annual market value of over $US4 billion (Krishan, 2007) .
Peptide-based inhibitors particularly suffer from short half-lives since they are often hydrophilic and thus show poor oral absorption and are rapidly cleared by the kidneys (Werle and Bernkop-Schnurch, 2006 ). In addition, peptide drugs are often quickly degraded by the numerous exo-and endo-proteases present in most tissues (Werle and BernkopSchnurch, 2006) . Even if intravenously administered, most peptides are cleared from the bloodstream within minutes. To overcome these particular challenges, peptide lead compounds often need to be modified in various ways, depending on the route of administration and the target tissue. N-and C-terminal modifications such as N-acetylation and C-amidation can reduce degradation by exoproteases (McGregor, 2008) . For example, the natural peptide thymopoietin involved in T-cell maturation has a half-life of 1 min in plasma, whereas a double end-capped version shows no detectable degradation (Heavner et al., 1986) . Similarly, capping with fatty acids can improve both the half-life and lipophilicity of a peptide, a technique used to improve serum stability of an anti-proliferative somatostatin analogue (Dasgupta et al., 2002) .
Backbone-and/or disulfide bond-circularised peptides are intrinsically stable to degradation, a common feature in naturally occurring peptides. A diverse range of plants produce cyclotides, circular miniproteins with a cysteine knot of three intertwined disulfides, believed to be involved in host defence (Craik et al., 2002; Gruber et al., 2008) . Many bacteria also produce circular peptides (bacteriocins) to target competing species (Mercedes et al., 2008) , as do many marine microorganisms (Hamada and Shioiri, 2005) . This approach was recently used by Clark et al. (2005) to produce a backbone-cyclised snail venom peptide (a-conotoxin) analogue with improved stability in serum.
A more significant challenge is to improve peptide resistance to endoprotease activity, since this involves peptide backbone and/or side chain modifications that are likely to have major effects on inhibitor potency and specificity. One strategy involves the substitution of certain amino acids that are known to be targets of proteolysis with non-natural Damino acids, as has been used to produce a variety of protease-resistant reagents including small peptides (Silvia et al., 2008) and antibodies (Webb et al., 2005) . Alternatively, substitution of peptide backbone atoms, in particular participants of the amide bond, can be used to produce what are commonly referred to as pseudopeptides. For example, the amide nitrogens of scissile bonds can be methylated (N-methylation) to prevent hydrolysis, as for the fungal peptide immunosuppressant cyclosporine A. This peptide has seven N-methylations, as well as one D-amino acid, and is highly bioavailable since it is chiefly degraded by the hepatic cytochrome P450 3A enzyme system rather than by proteases (Dunn et al., 2001 ). Recent advances in methods for synthesis of multi N-methylated peptides (Biron et al., 2006) have yielded a somatostatin analogue with four-fold higher half-life after oral administration (Biron et al., 2008) . A number of less commonly used amide bond surrogates also exist, including retro bonds (NH-CO), carba bonds (CH 2 CH 2 ), aza bonds (CO-NH-NR-CO), reduced amide (CH 2 NH) and urea bonds (HN-CO-NH). These have previously been reviewed elsewhere (Adessi and Soto, 2002; Lozano et al., 2006) .
Curiously, certain naturally occurring small protein inhibitors that deviate from Lipinski's rule of five are readily bioavailable. For example, orally administrated Bowman-Birk inhibitors (;8 kDa) are readily bioavailable (Kennedy, 1998) and the same is true for cyclotides (;3 kDa), at least in insects (Whetstone and Hammock, 2007) . There is a growing realisation that many of the issues above can be solved at a stroke by using naturally occurring inhibitors of serine proteases. For example, the inhibitors aprotinin (Terrell et al., 1996) and hirudin (Zeymer, 1998) have seen clinical use as modulators of bleeding after thoracic surgery and thrombolysis, respectively. The obvious next step for these naturally occurring inhibitors is to produce variants with redirected inhibitory specificity and enhanced potency. Use of these bioscaffolds is becoming increasingly common as their advantages in terms of stability, specificity and potency are recognised.
Engineered inhibitors: bioscaffolding
Bioscaffolding revolves around the use of natural template structures (bioscaffolds) in contrast to more conventional small-molecule approaches. Extensive use is made of preexisting natural protease inhibitors, which are re-engineered using recombinant DNA techniques or solid-phase peptide synthesis. The chief features of successful bioscaffolds are a structure that is both robust and flexible enough to tolerate multiple amino acid substitutions, and a template structure that has intrinsic protease inhibitor activity. Thus, the engineering goal is simply to redirect and enhance existing inhibitory activity. Further advantages come from facile production of inhibitor molecules in living systems, thus facilitating biopanning (phage display) and cheap and efficient large-scale bioproduction in microbial or plant systems.
Currently there are four classes of bioscaffold with relevance to kallikreins: serpins, Kunitz-domain inhibitors, ecotin and SFTI derivatives. All four classes of inhibitor interact with their target proteases through the canonical loop described above (Tyndall et al., 2005;  Figure 2E ), forming an extension of the protease b-sheet structure. However, the scaffolding presenting the reactive loop shows considerable structural diversity and plays varying roles in stabilising the protease-inhibitor complex. In addition to these four established bioscaffolds, there is also a move towards production of specific monoclonal antibodies that can inhibit kallikreins, with Dyax developing a specific KLK1 inhibitor for treatment of asthma (Sexton et al., 2009 ). This antibody was selected from a so-called Fab-on-phage library (Steukers et al., 2006) , which contains genes encoding the antibody heavy-and light-chain variable regions that are then displayed on the phage surface as Fabs and selected using surface plasmon resonance screening. Other non-clinical examples include antibody-mediated inhibition of KLK13 in a cell-based model of extracellular matrix degradation (Kapadia et al., 2004) and use in biochemical characterisation of KLK12 (Memari et al., 2007) . Both the bioscaffold and monoclonal antibody approaches make extensive use of phage display as a primary design tool. However, bioscaffold design is also driven by information from positional scanning and sparse matrix libraries, as outlined below.
Serpins
To date, three serpins have been exploited as bioscaffolds; C1-inhibitor protein, which inhibits the complement system (Kase and Pospisil, 1983) ; human a 1 -antitrypsin (AAT), which protects lung tissue from the effects of human neutrophil elastase (Sun and Yang, 2004) ; and human a 1 -antichymotrypsin (ACT), which is associated with the development of Alzheimer's disease (Potter et al., 2001 ). All three inhibitors are high-molecular-weight ()50 kDa) plasma proteins that contact their target proteases via a canonical loop, which is termed a reactive loop since it is cut by the target protease. Although the reactive loop does in theory control the majority of the specificity of a given serpin, there is also a significant contribution from serpin exosites such that swapping reactive loops alone between serpin subtypes is not sufficient to completely redirect their inhibitory activity (Djie et al., 1997) . Nonetheless, the reactive loop is very tolerant of substitution and this has led to the development of a series of recombinant kallikrein inhibitors.
Initially, an inhibitor for KLKB1 was developed using a variant of C1-inhibitor (Sulikowski et al., 2002) . C1-inhibitor effectively blocks KLKB1 activity and the aim of the reengineering was to increase the inhibition specificity and prevent the blockade of other complement proteases. Accordingly, a reactive loop variant was designed on the basis of the plasma KLK substrate specificity, which was previously assessed using a relatively small pool of arginine methyl esters (Levison and Tomalin, 1982) . The resulting variant showed the specificity required and maintained potency, with k a of 382 180 M -1 s -1
. Following this success, a KLK2 inhibitor was designed using ACT as bioscaffold (Cloutier et al., 2004) . The ACT reactive loop was substituted with a KLK2-specific sequence found through phage display (Cloutier et al., 2002) , yielding an inhibitor with a k a value of 6261 M -1 s -1 . More recently, Felber et al. (2006) re-engineered the reactive loop of both AAT and ACT serpins using pentapeptides derived from a phage display scan against immobilised KLK14 (Felber et al., 2005) . Currently, KLK2 ACT-derived inhibitors are being developed by Med Discovery, with the lead compound, MDKP67b, close to entering clinical trials as a targeted treatment for prostate cancer. The success of this approach owes much to the adaptability of the serpin reactive loop. In addition, using a human serpin as a bioscaffold, the problem of patient immune response to a protein therapeutic is neatly avoided.
Kunitz domain
Originally identified in BPTI, the Kunitz-domain inhibitory motif is remarkably compact and shows considerable thermal stability (Moses and Hinz, 1983; Makhatadze et al., 1993) . Both BPTI and the Alzheimer's amyloid b-protein precursor (APPI), which has a similar structure to BPTI, have been exploited as bioscaffolds. APPI was the first bioscaffold subjected to phage display. Screening against KLKB1 achieved a K i value of 15 pM . A later study searched for potent inhibitors of six distinct serine proteases, including KLKB1. This study focused on the BPTI canonical loop, substituting positions P1, P3 and P4 with amino-acid side chains gauged to explore the diversity of charge, shape and hydrophobicity. The best inhibitor against KLKB1 showed a k i value of 5.4 nM, a modest 2.2-fold improvement over the wild-type inhibitor; considerable thermal destabilisation was observed when P4 mutations were undertaken (Grzesiak et al., 2000b) .
The Kunitz-domain approach has also had some success in the world of commercial drug design and development, with a Dyax product, ecallantide (DX-88), reaching Phase III clinical trials for treatment of hereditary angioedema. Ecallantide was derived from a phage display screen of the Kunitz domain of human lipoprotein-associated coagulation inhibitor (LACI) using immobilised KLKB1 as bait. It has a reported K i value of 44 pM and is highly specific for KLKB1 (Williams and Baird, 2003) . At the time of writing, FDA approval for use of ecallantide was awaiting completion of a risk evaluation and mitigation strategy.
Ecotin
Ecotin (E. coli trypsin inhibitor) was isolated from the periplasmic space of E. coli and is a dimeric, bidentate protease inhibitor (Chung et al., 1983) . It is thought to provide protection against the effects of neutrophil elastase (Eggers et al., 2004) , which it inhibits with a K i value of 12 pM. Interaction between the protease and ecotin is driven by four loops (two from each ecotin monomer) and results in the formation of a heterotetramer with a very extensive buried surface area of 2850 Å 2 . Interestingly, binding by the contact loops is not restricted to the trypsin active site, but also includes residues that are highly divergent within the trypsin superfamily. Accordingly, these secondary contacts have the potential to provide greater selectivity than that of inhibitors that bind at the active site alone. This prompted Craik and co-workers (Stoop and Craik, 2003) to re-engineer the ecotin bioscaffold to produce a series of variant molecules that can inhibit KLKB1, thrombin, MT-SP1 and FXIIa. Two distinct design strategies were used, a simple progressive substitution of the ecotin apparent P1 residue and biopanning using phage display. Ecotin, like the C1-inhbitor bioscaffold, is a potent inhibitor of KLKB1 but lacks selectivity against other contact activation proteases. Given the role of the contact loops, as well as the canonical loop, in protease complex formation, a library of ecotin variants was produced by gene shuffling to target all five motifs. This library was screened against immobilised KLKB1 as described above and, in a novel Figure 2B ) (left) and subsequent complex formation via covalent bond formation with the Ser195 (catalytic) hydroxyl group (right). (C) Structure of a peptide aldehyde inhibitor (e.g., hK2p01, Figure 2B ) (left) and covalent bond formation with the Ser195 (catalytic) hydroxyl group (right). (D) Representation of a chloromethyl ketone inhibitor (e.g., CH-2856, Figure 2B ) (left) and mechanism of inhibition via dual linkage to the target protease at Ser195 (catalytic) as well as the adjacent His57 (catalytic) by the exposed CH 2 -Cl group (right).
deviation from the normal phage display procedure, the library was pre-blocked with soluble proteases from classes against which inhibitory activity was to be selected. This led to the isolation of an ecotin variant with a K i value for KLKB1 of 11 pM but with activity against factor Xa, factor XIa, urokinase-type plasminogen activator thrombin, and membrane-type serine protease 1 that is four to seven orders of magnitude lower (Stoop and Craik, 2003) .
Sunflower trypsin inhibitor
SFTI belongs to the Bowman-Birk serine protease inhibitor family and is a potent inhibitor of trypsin, cathepsin G and suppressor of tumourigenesis (14 ST14/matriptase/MT-SP1). It was originally discovered in sunflower (Helianthus annuus) seeds and characterised by determination of its three-dimensional structure in complex with bovine b-trypsin (Luckett et al., 1999) . Consisting of just 14 cyclised amino acids bisected by a disulfide bond, SFTI is intermediate between the macromolecular scaffolds represented by the bioscaffolds above and the small-molecule inhibitors described below. Its smaller size allows for facile chemical synthesis (Zablotna et al., 2002; Korsinczky et al., 2005) and rapid generation of variants. In addition, a very recent publication described expression of a library of fully cyclic SFTI variants in E. coli (Austin et al., 2009) , opening up the possibility of rapid in vivo screening.
Similar to the other bioscaffolds described above, SFTI interacts with its target proteases via a canonical-type loop. However, unlike the larger molecules, SFTI has essentially no molecular scaffolding behind it, relying on its fully cyclic backbone and a disulfide bond for stability. Interestingly, the structure of SFTI is maintained even when the disulfide is removed (by substituting glycine or aminobutyric acid), being preserved by an internal hydrogen bond network (Korsinczky et al., 2005) . However, this variant is not stable to cleavage by proteases. Surprisingly, there have been few attempts to use the SFTI molecule as a bioscaffold and the small number of variants produced have not been tested in cell culture or animal systems. To date, only KLK4 has been actively targeted; Swedberg et al. (2009) used a sparse matrix library approach to probe the KLK4 active site, and then substituted the optimal sequence obtained into the SFTI bioscaffold. This strategy improved both the potency and specificity of KLK4 inhibition by SFTI, increasing its potency by nearly two orders of magnitude to give a K i value of 3.6 nM. Moreover, the specificity of inhibition improved to give 500-fold selectivity against the closely related KLK14. Thus, in contrast to the situation for serpins described above, re-engineering of just three residues is sufficient to completely redirect the inhibitory activity of SFTI. This reflects the lack of interactions with regions outside the active-site cleft in the SFTI/protease complex.
Despite the inhibitory potency of these bioscaffolds, only ecallantide has successfully made the transition to clinical use. This may reflect the fact that ecotin, Kunitz-domain and serpin-based inhibitors are all macromolecular inhibitors requiring intravenous administration. Although the much smaller SFTI may yet prove to be readily bioavailable, detailed pharmacokinetics are currently unavailable for either wildtype or engineered versions of this scaffold. In addition, the other bioscaffold-based inhibitors show considerable crossreactivity between the kallikreins. Clearly there is considerable scope for further investigation focused on these remarkable reagents, which have the potential to become as successful as the small-molecule approaches conventionally applied to protease inhibitor design.
Engineered inhibitors: small-molecule inhibitors
The most commonly used small-molecule kallikrein inhibitors are serine protease-specific tetrahedral transition-state analogues. These include peptides in which the C-terminal carboxyl acid is substituted for boronic acid, an aldehyde or halogenated methyl ketones to form a tetrahedral adduct with Ser 195 (Figure 4 ). For example, Fareed et al. (1981) used KLK2 and KLKB1 kininogen cleavage sites to design peptide aldehyde inhibitors with K i values of 10-20 mM, although these inhibitors showed little specificity against a number of serine proteases of the blood clotting cascade. A boronic acid inhibitor based on a similar peptide sequence produced a potent (K i 150 pM) and more specific KLKB1 inhibitor (Dela Cadena et al., 1995) . Concurrently, Evans et al. (1996a,b) reported conservative non-natural amino acid substitutions of KLKB1 kininogen cleavage sites combined with a fluoroalkyloxymethyl ketone functionality to develop a series of specific KLK1 inhibitors with K i values in the lower nM range. These inhibitors attenuated breast cancer cell invasion in a Matrigel-based model (Wolf et al., 2001 ). More recently, the boronic acid approach was used to develop inhibitors to PSA; the best has a K i value of 65 nM (LeBeau et al., 2008) . However, there are limited specificity data available for these compounds and their biological impact is ambiguous.
Using a different strategy, Wanaka et al. (1990) capped phenylalanine N-terminally with benzylamine to yield a competitive KLKB1 inhibitor (K i 810 nM). This strategy, previously used to produce trypsin, plasmin and thrombin inhibitors (Markwardt et al., 1968) , capitalises on mimicking the P1 arginine by the benzylamine group; the 'peptide bond' is displaced, resulting in a non-hydrolysable compound. Various derivatives of this compound were later screened to produce a more potent KLKB1 inhibitor with a K i value of 130 nM (Teno et al., 1993) , although it suffers from the same lack of specificity as previous benzylamine derivatives (Markwardt et al., 1968) . b-Lactam analogues have also been used to produce a number of serine protease inhibitors (Konaklieva, 2002) , including a series of KLK3 inhibitors with inhibition in the nM range, although the specificity of this inhibition was not evaluated (Adlington et al., 1997 (Adlington et al., , 2001 .
Recently, phage display has been used to identify a series of KLK2 peptide inhibitors with inhibition constants in the lower micromolar range and selectivity over a number of tryptic serine proteases, including KLKB1 (Hekim et al., 2006) . The stability of these peptides was later improved by head-to-tail cyclisation and/or internal disulfide bond formation, without loss of potency (Pakkala et al., 2007) . The same group also produced three non-peptide KLK3 inhibitors with inhibition in the nanomolar range by screening against a library of small drug-like molecules (Koistinen et al., 2008b) . The development of these inhibitory peptides has recently been reviewed (Koistinen et al., 2008a) .
Small-molecule kallikrein inhibitors have not had the same clinical success as bioscaffold-based inhibitors. However, transition-state analogues are currently being investigated for use as activity-based probes, utilising the platform initially established for organophosphate peptide inhibitors (Liu et al., 1999) , which were developed to detect KLK6 . Clearly, the bioscaffold approach and conventional small-molecule design techniques are complementary.
Conclusions
There is increasing appreciation of the potential roles played by the kallikrein proteases as regulators of human physiology, as biomarkers in disease diagnosis and as points for therapeutic intervention. With application of the strategies we have discussed here, the next decade could see a blossoming of research in this area and the production of a new generation of protease inhibitor drugs to rival the antiviral protease inhibitors.
